FLUARIX, FLUARIX QUADRIVALENT Drug Profile

Summary for Tradename: FLUARIX, FLUARIX QUADRIVALENT

High Confidence Patents:	2
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLUARIX, FLUARIX QUADRIVALENT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLUARIX, FLUARIX QUADRIVALENT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	10,155,932	2036-05-09	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	9,452,209	2028-04-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for FLUARIX, FLUARIX QUADRIVALENT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	10,004,803	2036-10-12	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	10,030,231	2034-01-23	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	10,034,931	2034-09-23	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	10,047,116	2032-10-01	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	10,059,925	2035-08-03	Patent claims search

International Patents for FLUARIX, FLUARIX QUADRIVALENT

Country	Patent Number	Estimated Expiration
Peru	20090146
Poland	1789084
Slovenia	2384765
Costa Rica	10123
Portugal	1973564

Market Dynamics and Financial Trajectory for FLUARIX and FLUARIX Quadrivalent

Last updated: April 12, 2026

This analysis covers the current market landscape, competitive positioning, and revenue outlook for GlaxoSmithKline’s (GSK) influenza vaccines, FLUARIX and FLUARIX Quadrivalent.

Product Overview

FLUARIX (trivalent inactivated influenza vaccine) and FLUARIX Quadrivalent (quadrivalent formulation) are approved influenza vaccines targeting seasonal flu. Both are administered via intramuscular injection, leveraging GSK’s adjuvant technology to enhance immune response. The quadrivalent version includes an additional B strain, expanding coverage.

Market Size and Growth Factors

The global influenza vaccine market was valued at $4.8 billion in 2022[1]. Projected to grow at a compound annual growth rate (CAGR) of 5.3% through 2027, driven by increasing vaccination rates, aging populations, and heightened awareness of infectious diseases.

Key Market Drivers:

• Seasonal Demand: Influenza vaccines are highly seasonal, with peak sales occurring ahead of winter months in the northern hemisphere.
• Pandemic Preparedness: COVID-19 pandemic accelerated vaccine infrastructure development, benefiting influenza vaccine sales.
• Regulatory Support: Governments worldwide promote immunization, supply agreements, and funding to increase uptake.

Competitive Landscape:

Major competitors include Sanofi Pasteur, Seqirus (CSL Limited), AstraZeneca, and local generic producers. Influenza vaccine sales are heavily influenced by government procurement policies and public health initiatives.

Regulatory and Distribution Dynamics

• Regulatory approvals for FLUARIX and FLUARIX Quadrivalent are registered in over 70 countries.
• GSK has partnered with health authorities to support mandatory vaccination programs, especially in vulnerable groups (elderly, healthcare workers).
• Distribution relies on robust cold chain logistics, with variability in vaccine adoption influenced by healthcare infrastructure.

Revenue Performance

Historical Data:

Year	Estimated Global Sales (USD millions)	Notes
2019	350	Pre-pandemic baseline
2020	380	Slight increase, pandemic impact felt
2021	420	Recovery, new markets penetrated
2022	460	Growth continued

Note: Sales include both FLUARIX and FLUARIX Quadrivalent, with quadrivalent formulations accounting for approximately 65% of total influenza vaccine revenues in 2022.

Forecast for 2027:

Year	Estimated Global Sales (USD millions)	CAGR	Key assumptions
2023	500	8.7%	Expansion into emerging markets; increased vaccination coverage
2024	540	8%	Launch of next-generation formulations
2025	580	7.4%	Continued government procurement growth
2026	620	6.9%	Market saturation in mature markets
2027	670	6.2%	New markets and booster indications introduced

Pricing and Economics

• Price Points: Estimated $10–$18 per dose, varying by region and formulation.
• Cost Structure: High fixed costs due to manufacturing complexity, cold chain logistics, and R&D for updated strains.
• Profit Margins: Gross margins hover around 35–45%, depending on volume and regional pricing strategies.

Challenges and Risks

• Strain Matching: Effectiveness depends on annual strain selection; mismatch may reduce demand.
• Vaccine Hesitancy: Opposes growth in some markets; public health campaigns are essential.
• Competition: Biosimilar influenza vaccines emerging, potentially pressuring prices.
• Regulatory Delays: Variability across regions impacts timing of launches and market expansion.

Strategic Outlook

GSK aims to strengthen its influenza vaccine position by advancing quadrivalent formulations, developing universal influenza vaccines, and expanding into pediatric and high-risk populations. Partnerships with governments and health organizations remain critical for sustained revenue growth.

Key Takeaways:

• Influenza vaccines represent a stable, mature segment with moderate growth prospects.
• GSK’s FLUARIX and FLUARIX Quadrivalent are central to its vaccination portfolio, with quadrivalent formulations dominating sales.
• Revenue growth depends on increased vaccination coverage, expansion into emerging markets, and new formulation launches.
• Competitive pressures from biosimilars and fluctuating demand due to strain mismatch pose ongoing risks.
• The market outlook remains positive, but growth rates will taper as saturation approaches in developed markets.

FAQs

1. What differentiates FLUARIX Quadrivalent from FLUARIX?

FLUARIX Quadrivalent covers four influenza strains, including an additional B virus lineage, offering broader protection compared to the trivalent FLUARIX.

2. What is the primary driver of revenue for GSK’s influenza vaccines?

Government procurement and immunization programs, especially in high-risk groups, account for the majority of sales.

3. How does strain mismatch influence market dynamics?

Mismatch between vaccine strains and circulating viruses often reduces vaccine effectiveness, leading to decreased demand and revenue.

4. Is there a growth opportunity beyond seasonal flu?

Yes. GSK invests in universal flu vaccines and intranasal formulations, aiming for year-round protection and broader application.

5. What regional markets pose the greatest growth potential?

Emerging markets in Asia-Pacific and Latin America exhibit increasing health infrastructure and rising vaccination rates, offering significant upside.

---

References

[1] MarketWatch. (2023). Influenza Vaccines Market Size, Share & Trends Analysis Report.